Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ovarian Neoplasms

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 27 articles: HTML format

Single Articles

May 2025
1. SHAH M, Chen TY, Ison G, Fiero MH, et al
   Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
   J Clin Oncol. 2025 May 19:JCO2402834. doi: 10.1200/JCO-24-02834.
   PubMed     Abstract available
   
   
   January 2025
2. GAILLARD S, Lacchetti C, Armstrong DK, Cliby WA, et al
   Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.
   J Clin Oncol. 2025 Jan 22:JCO2402589. doi: 10.1200/JCO-24-02589.
   PubMed     Abstract available
   
   
   December 2024
3. SCAMBIA G, Villalobos Valencia R, Colombo N, Cibula D, et al
   Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.
   J Clin Oncol. 2024 Dec 12:JCO2400933. doi: 10.1200/JCO.24.00933.
   PubMed     Abstract available
   
   
   November 2024
4. FAGOTTI A, Costantini B, Fanfani F, Giannarelli D, et al
   Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18).
   J Clin Oncol. 2024 Nov 21:JCO2400686. doi: 10.1200/JCO.24.00686.
   PubMed     Abstract available
   
   
   October 2024
5. CHLEBOWSKI RT, Aragaki AK, Pan K, Haque R, et al
   Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials.
   J Clin Oncol. 2024;42:3537-3549.
   PubMed     Abstract available
   
   
   
6. BERGSTROM EN, Abbasi A, Diaz-Gay M, Galland L, et al
   Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides.
   J Clin Oncol. 2024;42:3550-3560.
   PubMed     Abstract available
   
   
   
7. LEE JM, Brady MF, Miller A, Moore RG, et al
   Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
   J Clin Oncol. 2024 Oct 3:JCO2400683. doi: 10.1200/JCO.24.00683.
   PubMed     Abstract available
   
   
   September 2024
8. GONZALEZ-MARTIN A, Rubio MJ, Heitz F, Depont Christensen R, et al
   Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
   J Clin Oncol. 2024 Sep 18:JCO2400668. doi: 10.1200/JCO.24.00668.
   PubMed     Abstract available
   
   
   August 2024
9. O'BRIEN KM, Wentzensen N, Ogunsina K, Weinberg CR, et al
   Intimate Care Products and Incidence of Hormone-Related Cancers: A Quantitative Bias Analysis.
   J Clin Oncol. 2024;42:2645-2659.
   PubMed     Abstract available
   
   
   May 2024
10. LANDEN CN, Buckanovich RJ, Sill MW, Mannel RS, et al
    Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
    J Clin Oncol. 2024 May 22:JCO2302076. doi: 10.1200/JCO.23.02076.
    PubMed     Abstract available
    
    
    
11. HARRIS HR, Davis CP, Terry KL
    Epidemiologic Methods to Advance Our Understanding of Ovarian Cancer Risk.
    J Clin Oncol. 2024 May 15:JCO2400602. doi: 10.1200/JCO.24.00602.
    PubMed    
    
    
    April 2024
12. MUTLU SUTCUOGLU B, Sutcuoglu O
    Interpretation of the EORTC-55954 Trial: Does the Response to Neoadjuvant Chemotherapy Have an Effect on Disease Outcome?
    J Clin Oncol. 2024;42:1204-1205.
    PubMed    
    
    
    
13. HAN CY, Lu KH, Corrigan G, Perez A, et al
    Normal Risk Ovarian Screening Study: 21-Year Update.
    J Clin Oncol. 2024;42:1102-1109.
    PubMed     Abstract available
    
    
    February 2024
14. LORUSSO D, Raspagliesi F, Ronzulli D, Valabrega G, et al
    Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
    J Clin Oncol. 2024 Feb 5:JCO2301225. doi: 10.1200/JCO.23.01225.
    PubMed     Abstract available
    
    
    
15. PAVLIK EJ, van Nagell JR Jr, Dietrich CS 3rd, Ueland FR, et al
    Compelling Story of Ovarian Cancer Screening.
    J Clin Oncol. 2024 Feb 2:JCO2302424. doi: 10.1200/JCO.23.02424.
    PubMed    
    
    
    January 2024
16. TJOKROWIDJAJA A, Friedlander ML, Ledermann JA, Coleman RL, et al
    Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
    J Clin Oncol. 2024 Jan 12:JCO2301182. doi: 10.1200/JCO.23.01182.
    PubMed     Abstract available
    
    
    November 2023
17. LAVERY JA, Boutros PC, Scott JM, Tammela T, et al
    Pan-Cancer Analysis of Postdiagnosis Exercise and Mortality.
    J Clin Oncol. 2023;41:4982-4992.
    PubMed     Abstract available
    
    
    
18. ST LAURENT J, Liu JF
    Treatment Approaches for Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2023 Nov 1:JCO2301771. doi: 10.1200/JCO.23.01771.
    PubMed     Abstract available
    
    
    October 2023
19. AREND RC, Monk BJ, Shapira-Frommer R, Haggerty AF, et al
    Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
    J Clin Oncol. 2023 Oct 31:JCO2202915. doi: 10.1200/JCO.22.02915.
    PubMed     Abstract available
    
    
    September 2023
20. OZOLS RF, Bundy BN, Greer BE, Fowler JM, et al
    Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study.
    J Clin Oncol. 2023;41:4077-4083.
    PubMed     Abstract available
    
    
    
21. SPRIGGS DR, Fleming GF
    Flashback Foreword: Cytoreductive Surgery for Ovarian Carcinoma and Carboplatin + Paclitaxel in Ovarian Cancer.
    J Clin Oncol. 2023;41:4063-4064.
    PubMed    
    
    
    August 2023
22. KURTZ JE, Pujade-Lauraine E, Oaknin A, Belin L, et al
    Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
    J Clin Oncol. 2023 Aug 29:JCO2300529. doi: 10.1200/JCO.23.00529.
    PubMed     Abstract available
    
    
    
23. MCCAW ZR, Tian L, Wei LJ
    Evaluating the Duration of Response With Mirvetuximab Soravtansine for Treating Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2023 Aug 3:JCO2300288. doi: 10.1200/JCO.23.00288.
    PubMed    
    
    
    June 2023
24. COLOMBO N, Van Gorp T, Matulonis UA, Oaknin A, et al
    Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
    J Clin Oncol. 2023 Jun 26:JCO2202624. doi: 10.1200/JCO.22.02624.
    PubMed     Abstract available
    
    
    May 2023
25. KINNEY AY, Walters ST, Lin Y, Lu SE, et al
    Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.
    J Clin Oncol. 2023;41:2767-2778.
    PubMed     Abstract available
    
    
    
26. STROOT IAS, Brouwer J, Bart J, Hollema H, et al
    High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors.
    J Clin Oncol. 2023;41:2523-2535.
    PubMed     Abstract available
    
    
    March 2023
27. FU S, Yao S, Yuan Y, Previs RA, et al
    Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification.
    J Clin Oncol. 2023;41:1725-1734.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.